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Abstract 
Background: The use of metformin after acute myocardial infarction (AMI) has been associated with reduced mortal‑
ity in people with type 2 diabetes mellitus (T2DM). However, it is not known if it is acutely cardioprotective in patients 
taking metformin at the time of AMI. We compared patient outcomes according to metformin status at the time of 
admission for fatal and non‑fatal AMI in a large cohort of patients in England.
Methods: This study used linked data from primary care, hospital admissions and death registry from 4.7 million 
inhabitants in England, as part of the CALIBER resource. The primary endpoint was a composite of acute myocardial 
infarction requiring hospitalisation, stroke and cardiovascular death. The secondary endpoints were heart failure (HF) 
hospitalisation and all‑cause mortality.
Results: 4,030 patients with T2DM and incident AMI recorded between January 1998 and October 2010 were 
included. At AMI admission, 63.9% of patients were receiving metformin and 36.1% another oral hypoglycaemic 
drug. Median follow‑up was 343 (IQR: 1–1436) days. Adjusted analyses showed an increased hazard of the compos‑
ite endpoint in metformin users compared to non‑users (HR 1.09 [1.01–1.19]), but not of the secondary endpoints. 
The higher risk of the composite endpoint in metformin users was only observed in people taking metformin at 
AMI admission, whereas metformin use post‑AMI was associated with a reduction in risk of all‑cause mortality (0.76 
[0.62–0.93], P = 0.009).
Conclusions: Our study suggests that metformin use at the time of first AMI is associated with increased risk of car‑
diovascular disease and death in patients with T2DM, while its use post‑AMI might be beneficial. Further investigation 
in well‑designed randomised controlled trials is indicated, especially in view of emerging evidence of cardioprotec‑
tion from sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors.
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Background
In acute myocardial infarction (AMI), early reperfusion 
by primary percutaneous coronary intervention (PPCI) is 
the most effective strategy for reducing infarct size and 
improving clinical outcome [1, 2]. However, 30  day all-
cause mortality following PPCI remains significant and 
strategies to further improve outcomes are essential [3]. 
This mortality might be partly explained by the injury 
inflicted by the therapeutic restoration of blood flow, 
known as ischaemia–reperfusion injury (IRI), which may 
account for up to 50% of final infarct size [4–7].
Diabetes mellitus is a major risk factor for coronary 
heart disease (CHD), and patients with diabetes and 
CHD have poor clinical outcomes [8, 9]. Metformin, an 
oral antidiabetic of the biguanide class, exerts its effect 
by increasing gluconeogenesis and increasing periph-
eral glucose uptake. The UK Prospective Diabetes Study 
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(UKPDS) was a large randomised, multicentre trial of 
glycaemic therapies in patients with newly diagnosed 
type 2 diabetes mellitus (T2DM) [8]. It showed lower risk 
of AMI in metformin users than in participants on diet 
therapy alone. Furthermore, all-cause and cardiovascular 
mortality was lower in metformin users than in sulfony-
lurea and insulin users, despite achieving similar glycae-
mic control. However, the role of metformin in reducing 
cardiovascular disease remains controversial, with no 
cardiovascular outcomes achieving statistical significance 
in a recent meta-analysis [10].
Nonetheless, the potential for metformin to confer 
acute cardioprotection in AMI is well established in the 
pre-clinical literature [11–15]. It has been hypothesized 
that the favorable effects of pre-treatment with met-
formin in patients with AMI relate to cardioprotection 
against IRI, independent of its hypoglycaemic actions 
[14]. However, to our knowledge, no studies have inves-
tigated outcomes after AMI in diabetic patients pre-
treated with metformin, with the exception of mixed 
results from studies investigating the association between 
metformin treatment prior to ST-segment elevation AMI 
(STEMI) and infarct size (defined using serum biomark-
ers as surrogate measures) and left ventricular (LV) func-
tion [16, 17]. A mortality benefit of pre-treatment with 
metformin has not been demonstrated in patients with 
AMI and, using linked electronic health records from the 
CALIBER resource, which prospectively records medica-
tion status, we investigated whether metformin admin-
istration is associated with cardioprotection to these 
patients. Metformin is cheap and widely available, so 
reducing the ambiguity over its role as a cardioprotective 
adjunct in AMI could have global relevance [18].
Methods
Study design and data sources
This study used linked longitudinal electronic health 
records from the Clinical Practice Research Datalink 
(CPRD), Hospital Episode Statistics (HES) and cause-
specific mortality from the Office for National Statis-
tics (ONS) in England, which are part of the CALIBER 
resource (https ://www.calib erres earch .org). Further 
details are provided in Additional file 1: Additional meth-
ods. This was a prospective cohort study and Additional 
file  1: Table  S1 summarizes the STROBE and RECORD 
checklists for reporting on observational research [19, 
20].
Study population and exposure definition
The study included all available patients with T2DM 
experiencing their first fatal or non-fatal AMI (either 
STEMI or non-STEMI) between January 1998 and Octo-
ber 2010. Diagnoses of T2DM and AMI were identified 
in CPRD and HES using EHR-derived phenotypes 
[21, 22]. Only the earliest recorded AMI across all data 
sources was considered [21, 23, 24]. Eligibility criteria 
for study inclusion were no history of AMI prior to the 
study start date, a minimum of 1 year of follow-up since 
practice registration and since the date on which the data 
from their CPRD practice was deemed to be of accept-
able quality, and be 18 years of age or above at the time 
of AMI admission. Metformin exposure status at AMI 
admission was defined according to whether the patient 
had at least one prescription within 6 months before the 
incident AMI. After AMI, if repeat prescriptions were at 
least 6 monthly, patients were defined as having ongoing 
drug exposure during follow-up. This was used as a time-
updated covariate in survival analysis.
Baseline characteristics
To account for recent diabetes severity, it was determined 
whether a patient was prescribed insulin in 6  months 
prior to hospital admission. Glycosylated haemoglobin 
was included, when it was recorded within a year prior 
to admission, as a marker of glycaemic control. For each 
patient, data on diagnosed co-morbidities and cardiovas-
cular risk factors were identified in CPRD, HES and ONS 
[25]. Further details are provided in Additional file  1: 
Additional methods.
Study endpoints and follow‑up
The primary endpoint was a major adverse cardiac event 
(MACE), defined as a composite of AMI requiring hos-
pitalisation, stroke and cardiovascular mortality. The 
secondary endpoints were hospitalisation for heart fail-
ure (HF) and all-cause mortality. An a priori subgroup 
analysis included only survivors of AMI at 30 days post-
index AMI (i.e. those who left the GP practice, were ‘lost 
to follow-up’ or had an event within 30  days post-AMI 
were excluded), to distinguish between acute and chronic 
effects of metformin after AMI. Further details are pro-
vided in Additional file 1: Additional methods.
Statistical analyses
Demographic and baseline characteristics of the study 
population with and without metformin were compared 
using the Pearson Chi square test for categorical variables 
and Student t test for continuous variables. The cumula-
tive probability of each endpoint was calculated using 
Kaplan–Meier methods and the log rank test was used to 
examine differences between the treatment groups. Mul-
tivariable Cox proportional hazard regression was used 
to estimate hazard ratios for the effect of metformin use 
at AMI admission, adjusted for covariates where P < 0.2 
in the univariable analysis or their inclusion in the mod-
els resulted in a change of the estimate of the exposure 
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of > 10%, as well as the a priori well established cardio-
vascular risk factors age, sex, BMI and smoking status at 
time of index AMI. Further details are provided in Addi-
tional file 1: Additional methods.
Sensitivity analyses
Sensitivity analyses were performed to examine the 
effect of ongoing metformin use, which has previously 
been associated with benefit [10]. To do so, we compared 
patients on metformin at the time of index AMI who had 
no subsequent prescriptions with those who were never 
prescribed metformin or had their first prescription after 
6 months post-AMI, at which point they were censored). 
Patients with a metformin prescription within 6 months 
after first AMI were excluded from this analysis. We also 
analysed time-varying metformin use for patients who 
did not have a metformin prescription at AMI admission 
and within 6 months of AMI, for comparison with pre-
vious studies. As an alternative approach, we conducted 
a propensity score analysis. Propensity scores (the con-
ditional probability that a subject received metformin) 
were predicted for each subject using baseline covari-
ates in a logistic regression model. All available baseline 
covariates were considered, but only those that showed 
evidence of an association with the outcome were used 
in the final model [26, 27]. The propensity scores were 
assessed in each treatment group to ensure balance. 
Details of the composition of the propensity score model 
is given in Additional file  1. The estimated propen-
sity scores were then used to create inverse probability 
weights for each subject [28]. These weights were used in 
a Cox proportional hazards regression model to estimate 
the treatment group effect. Further sensitivity analyses 
are described in Additional file 1: Additional methods.
Results
Metformin use and patient baseline characteristics
Out of 4,703,682 patients in CALIBER, we identified 
4030 eligible patients with T2DM and no history of HF 
or AMI, who had an incident AMI during the study 
period (Fig.  1). Of them, 2576 (63.9%) were prescribed 
metformin at the time of their AMI while 1454 (36.1%) 
received an alternative hypoglycaemic drug. The median 
follow-up time from first AMI (index event) to either 
death, leaving their GP practice or last date of data col-
lection was 343 (IQR: 1–1436) days.
Patient baseline characteristics according to expo-
sure group are shown in Table 1. The mean age at index 
AMI admission was lower for metformin users than for 
those taking an alternative hypoglycaemic drug (71.3 and 
76.1  years, respectively), and there was a lower propor-
tion of women (38.9% vs. 42.9%). Overall, co-morbidities 
and cardiovascular risk factors were similar between the 
two treatment groups (Table 1). Although more patients 
in the metformin group had a raised BMI and history 
of smoking, fewer had a history of peripheral arterial 
disease (PAD) and abdominal aortic aneurysm (AAA). 
Importantly, there was no clinically meaningful dif-
ference in glycaemic control, indicated by the level of 
HbA1c, between the two groups (metformin 61.5 mmol/
Fig. 1 Study flow diagram. MACE, major adverse cardiac events, defined as a composite of AMI requiring hospitalisation, stroke and cardiovascular 
mortality. UTS, up to standard; AMI, acute myocardial infarction; HF, heart failure
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mol vs. other hypoglycemics 59.0  mmol/mol, median 
time of measurement 96 (IQR 46–168) days prior to 
index AMI). More patients on metformin had recently 
been prescribed insulin (17.1% vs. 7.8%). Use of other 
oral hypoglycaemic medication was similar except for 
sulphonylureas, which were unsurprisingly higher in the 
non-metformin group (50.9% vs. 96.3%).
Table 1 Baseline patient characteristics by metformin status, in patients with at least one prescription in 6 months prior 
to admission with first acute AMI
Patients with missing data were: 16 for IMD score, 210 for BMI, 188 for smoking status, 91 for systolic blood pressure, 1032 for HbA1c, 988 for HDL cholesterol, and 382 
for total cholesterol
AMI acute myocardial infarction, BMI body mass index, IMD index of multiple deprivation, HbA1c haemoglobin A1c, DPP dipeptidyl peptidase, GLP glucagon-like 
peptide, HDL high density lipoprotein, HF heart failure, CHD coronary heart disease, NOS not otherwise specified, TIA transient ischaemic attack, PAD peripheral arterial 
disease, AAA abdominal aortic aneurysm
* P < 0.05 ** P < 0.001, from tests of difference using t tests for continuous variables and Chi squared tests for categorical variables
Metformin (N = 2576, 63.9%) Other drug 
(N = 1454, 
36.1%)
Age (years), mean (SD)** 71.29 (11.2) 76.10 (10.9)
Female, n (%)* 1001 (38.9) 624 (42.9)
IMD, n (%)
 < 8.5 (Least deprived) 431 (16.8) 252 (17.4)
 8.5– < 34.18 1657 (64.6) 938 (64.8)
 ≥ 34.18 (Most deprived) 478 (18.6) 258 (17.8)
BMI (kg/m2), mean (SD)**
 < 18.5 23 (0.9) 27 (2.0)
 18.5– < 25 490 (19.8) 388 (29.0)
 25– < 30 912 (36.8) 535 (40.0)
 30– < 35 703 (28.4) 275 (20.5)
 ≥35 352 (14.2) 115 (8.6)
Smoking status, n (%)*
 Never‑smoker 1104 (44.6) 688 (50.4)
 Ex‑smoker 1011 (40.8) 493 (36.1)
 Current smoker 363 (14.7) 183 (13.4)
Hypertensive, n (%)* 2186 (84.9) 1178 (81.0)
Systolic blood pressure (mmHg), mean (SD)* 140.50 (23.6) 138.38 (21.8)
HbA1c (mmol/mol), mean (SD)** 61.48 (17.39) 58.99 (17.16)
Diabetes medication, n (%)
 Sulphonylureas, n (%)** 1310 (50.9) 1400 (96.3)
 Thiazolidinediones, n (%) 217 (8.4) 146 (10.0)
 Acarbose, n (%) 69 (2.7) 37 (2.5)
 DPP4 inhibitors, n (%)* 8 (0.3) 13 (0.9)
 GLP1 agonists, n (%) 3 (0.1) 2 (0.1)
 Meglitinides, n (%) 21 (0.8) 15 (1.0)
 Insulin, n (%)** 440 (17.1) 113 (7.8)
 HDL serum cholesterol (mmol/L), mean (SD) 1.18 (0.4) 1.20 (0.4)
 Total serum cholesterol (mmol/L), mean (SD)** 4.43 (1.2) 4.58 (1.3)
History of cardiovascular disease
 HF, n (%)* 652 (25.3) 432 (29.7)
 CHD, n (%) 1064 (41.3) 593 (40.9)
 Ischaemic stroke, n (%) 89 (3.5) 49 (3.4)
 Stroke, n (%) 338 (13.1) 198 (13.6)
 TIA, n (%) 218 (8.5) 135 (9.3)
 PAD, n (%)* 472 (18.3) 307 (21.1)
 AAA, n (%)* 441 (17.1) 292 (20.1)
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Associations between metformin use at AMI admission 
and endpoints
In total, 2450 patients had a MACE endpoint during the 
study period, 1551 (60.2%) in metformin users at the time 
of their AMI and 899 (61.8%) in non-users (Table 2). The 
unadjusted analysis showed no statistically significantly 
difference between metformin user groups at hospi-
tal admission for AMI (HR 0.95 [0.88–1.03], P = 0.239, 
Table 2). In adjusted models, there was strong evidence 
of an association with the composite endpoint amongst 
metformin users, but the HR was small (HR 1.09 [1.01–
1.19], P = 0.034, Table 2).
The median time to outcome diagnosis was 55 (IQR 
0–396) days. Sequential adjustment revealed that adjust-
ing only for age (HR 1.10 [1.01–1.19], P = 0.033) had the 
largest impact on the change in the size of the hazard 
ratio compared to the crude estimate. Further adjust-
ment for other baseline covariates (sex, BMI, prior insu-
lin use, total serum cholesterol, previous stroke and 
previous TIA) had only small added effects (Additional 
file 1: Table S2). Furthermore, there was no evidence for 
an interaction between metformin use and AMI type 
(P = 0.274, Additional file  1: Table  S2). The propensity 
score analysis showed consistent results (HR 1.13 [1.03–
1.23], P = 0.006, Table  3) for the composite primary 
endpoint. This association was driven by an increased 
hazard of cardiovascular mortality (HR 1.12 [1.00–1.25], 
P = 0.044), which was not evident in the main analysis.
With respect to the secondary endpoints, the use of 
metformin at the time of index AMI was associated 
with a trend towards increased risk of HF hospitalisa-
tion (HR 1.13 [0.98–1.30], P = 0.098, Table  2) but not 
all-cause mortality (HR 0.97 [0.89–1.04], P = 0.395, 
Table 2). However, in the propensity score analysis, this 
association with increased HF hospitalisation reached 
statistical significance (Table 3).
Subgroup analysis restricted to survivors after 30 days 
post index AMI showed no association between met-
formin use and MACE (HR 1.06 [0.95–1.17], P = 0.305, 
Additional file 1: Table S3).
Table 2 Associations between  metformin use at  hospital admission for  AMI and  MACE over  median follow-up of  343 
(IQR: 1–1436) days
AMI acute myocardial infarction, HF heart failure
a Adjusted for: age at index AMI, sex, smoking status, BMI, prior insulin use, total serum cholesterol, previous stroke, previous TIA
Number of patients experiencing event 
(%)
Unadjusted Adjusteda
Metformin (N = 2576) Other (N = 1454) Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Primary endpoint
 MACE (composite of cardio‑
vascular mortality, AMI and 
stroke)
1551 (60.2) 899 (61.8) 0.95 (0.88–1.03) 0.239 1.09 (1.01–1.19) 0.034
Components of primary endpoint
 Cardiovascular mortality 894 (34.7%) 584 (40.2%) 0.84 (0.76–0.93) 0.001 1.06 (0.96–1.17) 0.275
 AMI 807 (31.3%) 433 (29.8%) 1.01 (0.90–1.14) 0.887 1.06 (0.94–1.20) 0.363
 Stroke 294 (11.4%) 195 (13.4%) 0.84 (0.70–1.00) 0.051 0.99 (0.82–1.19) 0.904
Secondary endpoints
 All‑cause mortality 1423 (55.2%) 1020 (70.2%) 0.77 (0.71–0.83) < 0.001 0.97 (0.89–1.04) 0.395
 HF hospitalisation 589 (22.9) 313 (21.5) 1.01 (0.88–1.16) 0.918 1.13 (0.98–1.30) 0.092
Table 3 Associations between  metformin use at  hospital 
admission for  AMI and  MACE over  median follow-up 
of 343 (IQR 1–1436) days using propensity score analysis
Adjusted for: age at index AMI, sex, ethnicity, BMI, fasted glucose, HbA1c, 
smoking status, total serum cholesterol, previous HF, previous stroke, previous 
TIA, previous AAA, previous angina and if ever prescribed insulin prior to index 
AMI
AMI acute myocardial infarction, HF heart failure
Endpoint Hazard ratio (95% CI) P value
Primary endpoint
 MACE (composite of cardiovascu‑
lar mortality, AMI and stroke)
1.13 (1.03–1.23) 0.006
Components of primary endpoint
 Cardiovascular mortality 1.12 (1.00–1.25) 0.044
 AMI 1.07 (0.95–1.21) 0.273
 Stroke 1.00 (0.83–1.21) 0.977
Secondary endpoints
 All‑cause mortality 1.02 (0.94–1.11) 0.660
 HF hospitalisation 1.18 (1.06–1.31) 0.002
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Sensitivity analyses
Metformin use at the time of index AMI but not after-
wards, compared to no metformin use, was associated 
with an increased hazard of the primary composite out-
come (HR 1.41 [1.28–1.56], P < 0.001, Additional file  1: 
Table S4). This was driven by an increase in the hazard of 
cardiovascular mortality (HR 1.50 [1.33–1.68], P < 0.001). 
Patients on metformin at the time of index AMI who 
had no subsequent prescriptions of this drug had an 
increased hazard of all-cause mortality (HR 1.31 [1.19–
1.43], P < 0.001) but the association with HF hospitalisa-
tion was not statistically significant (HR 1.12 [0.98–1.45], 
P = 0.078, Additional file 1: Table S4).
In the analysis of time-varying metformin use post-
AMI in patients who were not on metformin at the 
time of AMI, the hazard of MACE was similar during 
periods of metformin use compared to periods of non-
use (HR 0.96 [0.78–1.19], P = 0.732). However, consist-
ent with previous reports, all-cause mortality was lower 
during periods of metformin use (HR 0.75 [0.62–0.93], 
P = 0.009) in this cohort, as was the hazard of hospi-
talised HF, although this did not reach statistical sig-
nificance (HR 0.67 [0.47–1.01], P = 0.056). There was no 
evidence of association with cardiovascular mortality 
(HR 0.88 [0.67–1.15], P = 0.345). Additional sensitivity 
analyses are described in Additional file  1: Additional 
results.
Discussion
Based on previous basic and clinical studies, we hypoth-
esised that metformin administration would confer car-
dioprotection in the setting of AMI. We interrogated 
linked, prospectively recorded, electronic health records 
of patients with T2DM experiencing their first AMI, 
using primary care linked to hospital admission and mor-
tality data. This is the first study investigating the asso-
ciation of outcomes after AMI in diabetic patients with 
metformin pre-treatment. We observed an older cohort, 
higher rates of previous cardiovascular disease and worse 
outcomes compared to other studies of AMI in dia-
betic patients [29, 30], indicating that ours is a high-risk 
cohort.
Metformin use at time of AMI
Among over 4000 patients identified, the majority were 
receiving metformin at the time of index AMI, which 
was associated with worse outcomes with respect to the 
composite endpoint compared to patients on alterna-
tive oral hypoglycaemic agents. This which was driven by 
cardiovascular mortality and was the case despite similar 
glycaemic control in the two treatment groups, albeit it 
with higher rates of insulin prescription in the metformin 
group. This association was not evident in patients who 
survived the first month post index AMI, suggesting an 
acute, non-lasting effect. Interestingly, these findings 
only applied to patients taking metformin at the time of 
AMI, whereas post-AMI metformin use was associated 
with similar or reduced risk (and attenuated the strength 
of association in the primary analysis), in keeping with 
previous reports [31]. Taken together and acknowledg-
ing potential bias associated with observational studies 
(including a more severe diabetes phenotype as indicated 
by a higher use of insulin in metformin users), these find-
ings challenge reports of an acute infarct-sparing role for 
metformin.
With respect to cardioprotection at the time of AMI, 
several preclinical studies have demonstrated acute 
infarct size reduction and improved cardiac function 
with metformin [11–15]. However, a recently published 
pre-clinical study of post-conditioning with metformin 
in pigs found no difference in infarct size or LV func-
tion compared to vehicle [32]. Human studies have used 
biomarkers as a surrogate of infarct size in the context 
of STEMI [16, 17]. A study of 660 diabetic patients with 
STEMI showed a reduction of infarct size (according to 
serum biomarkers) in the metformin group, although 
the comparator group were treated with diet alone, 
which may have exaggerated the effect [16]. A propen-
sity score matched analysis of 493 diabetic patients with 
STEMI showed no association between metformin and 
infarct size or LV function, although no information 
on drug treatment of diabetes in the control group was 
provided [17]. In an analogous, randomized trial of oral 
metformin, started after primary percutaneous coronary 
intervention for STEMI in patients without diabetes, no 
benefit was seen on LV function, MACE, all-cause mor-
tality, or new-onset diabetes [33, 34].
Our data also applies to patients with non-ST-segment 
elevation AMI (NSTEMI). Despite worse outcomes than 
patients presenting with STEMI [35, 36], there is no evi-
dence regarding the use of metformin in this context. We 
report an association between metformin use at the time 
of index AMI, including NSTEMI, and worse outcomes. 
This was unexpected and justifies further investigation.
We were unable to investigate the reasons for the 
association with worse outcomes in patients taking 
metformin at the time of index AMI. Traditionally, met-
formin is stopped on admission in these patients, due to 
concerns over lactic acidosis. However, there is a paucity 
of evidence for this and guidelines from the European 
Society of Cardiology (ESC) no longer recommend its 
routine cessation [37–40]. Our findings may also relate 
to the metformin group being a sicker cohort with worse 
diabetic phenotypes as indicated by a higher use of insu-
lin in metformin users. In critically ill patients there is 
a risk of hypoglycaemia-related morbidity associated 
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with intensive glucose control with intravenous insulin 
[41, 42], although we did not have data on acute glucose 
control in our study. In pre-clinical studies, increased 
myocardial rupture after AMI has been observed with 
metformin, which has been attributed to increased 
AMPK-MTOR/PGC-1α-mediated cardiomyocyte 
autophagy, but we were unable to assess this [43].
Metformin use post‑AMI
Despite these findings, metformin treatment has been 
shown to be advantageous in several pre-clinical and 
clinical studies of various cardiovascular diseases [44–
47]. Beneficial effects on mortality have been reported in 
patients started on metformin after AMI, independent of 
its hypoglycaemic actions [31]. This is typically attributed 
to the prevention of adverse ventricular remodelling [48, 
49]. However, these potential effects remain controversial 
and a recent meta-analysis of randomised trials indicated 
a non-statistically significant reduction of risk for most 
outcomes in metformin users, compared to non-users 
[10]. In the present study, metformin use post-AMI was 
associated with a lower hazard ratio of MACE, which 
may support its use in patients at increased risk of car-
diovascular disease.
Clinical relevance and further work
The ESC advocate the use of metformin, despite limited 
evidence, because of potential safety and economic ben-
efits [50]. The present study is consistent with its use in 
patients with T2DM but the association with worse out-
comes among patients on metformin at the time of their 
AMI suggests that further investigation in well-designed 
randomised controlled trials is indicated, especially 
in view of the evidence and availability of alternatives. 
Although de novo randomised controlled trials of met-
formin are unlikely, the present study supports recent 
assertions that alternative approaches may comprise the 
inclusion of metformin in factorial trials and full publica-
tion of cardiovascular outcome data from previous trials 
of metformin [10].
Strengths and limitations
The strengths of this study include, first, the use of three 
linked electronic data sources to maximise the ascertain-
ment of outcomes. In addition, medication status and 
baseline characteristics were recorded prospectively, 
prior to AMI, limiting the possibility of recall bias. Sec-
ond, the longitudinal study design and the analysis of 
metformin as a time-varying covariate that consider 
periods of use and non-use during follow-up. Third, we 
included patients on alternative hypoglycemics as the 
control group. This contrasts with similar studies that use 
a non-diabetic or untreated diabetic patient control arm 
and risk confounding due to difference in baseline char-
acteristics. The results from the propensity score analy-
sis were consistent, which increases confidence in our 
findings.
This study has the limitations of observational data, 
including potential bias because of unmeasured con-
founding factors (e.g. reperfusion status and indication 
bias). Therefore, we can only report associations and not 
causal relationships, and any results must be interpreted 
with caution, especially in view of clinical experience and 
economic indications for metformin use. Furthermore, 
although we accounted for HbA1c and prior insulin use, 
we were unable to adjust for other indicators of qual-
ity of diabetes management, including microvascular 
and other macrovascular complications, as these data 
were unavailable. However, the baseline characteristics 
of patients in our cohort were similar to each other and 
to those reported elsewhere [16]. Further strengths and 
limitations are addressed in Additional file 1: Additional 
discussion.
Conclusions
Acknowledging the limitations of observational stud-
ies, this study suggests that metformin use at the time of 
AMI is associated with increased risk of cardiovascular 
disease and death in patients with T2DM, while its use 
post-AMI might be beneficial. This may relate to the met-
formin group being a sicker cohort with worse diabetic 
phenotypes. However, evidence for metformin in diabetic 
patients at high cardiovascular risk is mixed and resolv-
ing this is central to extracting maximum benefit from 
this cheap and widely available drug.
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